Also, Long Term Hospital Adjustment
to be Implemented this Summer
CMS announced
last weekend that government auditors, upon reviewing claims data for Trastuzumab
(Herceptin) for the last several years, found “numerous instances” of incorrect
billing for multi-use vials in cases in which some of the medication was
wasted.
The agency stated, “Multi-use vials
are not subject to payment for discarded amounts of drug or biological,” and
referred providers to Chapter
17, Section 40 of the Medicare Claims Processing Manual.
The Institute for Clinical and
Economic Review announced
last July that the breast cancer drug, trastuzumab deruxtecan, may be the subject
of an ICER review this year.
CMS also announced that
the Long Term Care Hospital (LTCH) Discharge Payment Percentage (DPP) Payment
Adjustment will be “implemented” on July 6.
No comments:
Post a Comment